Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02227875 · ClinicalTrials.gov registry record · Phase 3
Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 2 Diabetes Mellitus Patients (INSTRIDE 2)
A Phase 3 study, sponsored by Mylan.
- Completed
- Registry status
- Phase 3
- Development phase
- 560
- Enrollment target
NCT02227875 is a Phase 3 study that has completed, run by Mylan. The registered enrollment target is 560 participants.
The verdict
NCT02227875, a Phase 3 study, has completed, sponsored by Mylan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 560 participants
- Enrollment target
Study Summary
To test whether Mylan's insulin glargine once daily is non-inferior to Lantus® once daily (both administered in combination with other anti-diabetic drugs) based on the change in HbA1c from baseline to 24 weeks
Interventions
- DRUG Mylan's insulin glargine
- DRUG Lantus®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 560 participants |
| Start Date | 2014-08 |
| Est. Completion | 2015-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02227875
The ClinicalTrials.gov registry entry for NCT02227875 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 560 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mylan, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Mylan's insulin glargine is the first listed.
NCT02227875 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02227875 about?
NCT02227875 is a clinical study titled "Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 2 Diabetes Mellitus Patients (INSTRIDE 2)". To test whether Mylan's insulin glargine once daily is non-inferior to Lantus® once daily (both administered in combination with other anti-diabetic drugs) based on the change in HbA1c from baseline to 24 weeks
What is the current status of trial NCT02227875?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 560 participants. The study started on 2014-08. Estimated completion is 2015-12.
What interventions are being tested in trial NCT02227875?
The interventions under investigation include: Mylan's insulin glargine (DRUG), Lantus® (DRUG).
Who is sponsoring clinical trial NCT02227875?
This trial is sponsored by Mylan, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.